CLINICAL TRIALS PROFILE FOR INSULIN GLARGINE

Biosimilar Clinical Trials for insulin glargine

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03819790 ↗	The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians	Completed	Sanofi	Phase 4	2018-10-02	The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM).
NCT03819790 ↗	The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians	Completed	LMC Diabetes & Endocrinology Ltd.	Phase 4	2018-10-02	The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM).
NCT04591457 ↗	The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus	Not yet recruiting	Indonesia University	Phase 2	2020-10-01	This is an open-label randomised multicenter clinical study to investigate efficacy, safety, and immunogenicity of the drug products: Insulin Glargine biosimilar ® Log-G and its reference Lantus® in type 2 diabetes mellitus patients
NCT06624943 ↗	Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali	COMPLETED	Centre Hospitalier du Luxembourg	PHASE4	2022-03-14	This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe.
NCT06624943 ↗	Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali	COMPLETED	Hospital of Mali	PHASE4	2022-03-14	This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe.
NCT06624943 ↗	Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali	COMPLETED	Sante Diabete Mali	PHASE4	2022-03-14	This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe.

All Clinical Trials for insulin glargine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00046462 ↗	Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment	Completed	Sanofi	Phase 3	2001-11-01	The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
NCT00064714 ↗	Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-07-01	This study will determine 1) the safety of AC2993 in patients with type I diabetes; 2) the ability of AC2993 to improve beta cell function; and 3) the effects of immunosuppression on beta cell function. Type I diabetes is an autoimmune disease, in which the immune system attacks the beta cells of the pancreas. These cells produce insulin, which regulates blood sugar. AC2993 may improve the pancreas's ability to produce insulin and help control blood sugar, but it may also activate the original immune response that caused the diabetes. Thus, this study will examine the effects of AC2993 alone as well as in combination with immunosuppressive drugs. Patients between 18 and 60 years of age who have type I diabetes mellitus may be eligible for this 20-month study. They must have had diabetes for at least 5 years and require insulin treatment. Candidates will be screened with a questionnaire, followed by medical history and physical examination, blood and urine tests, a chest x-ray and skin test for tuberculosis, electrocardiogram (EKG), and arginine stimulated C-peptide test (see description below). Participants will undergo the following tests and procedures: Advanced screening phase: Participants undergo a diabetes education program, including instruction on frequent blood glucose monitoring, dietary education on counting carbohydrates, intensive insulin therapy, review of signs and symptoms of low blood sugar (hypoglycemia), and potential treatment with glucagon shots. Patients must administer insulin via an insulin pump or take at least four injections per day including glargine (Lantus) insulin. 4-month run-in phase - Arginine-stimulated C-peptide test: This test measures the body's insulin production. The patient is injected with a liquid containing arginine, a normal constituent of food that increases insulin release from beta cells into the blood stream. After the injection, seven blood samples are collected over 10 minutes. - Mixed meal stimulated C-peptide test with acetaminophen: This test assesses the response of the beta cells to an ordinary meal and the time it takes for food to pass through the stomach. The patient drinks a food supplement and takes acetaminophen (Tylenol). Blood samples are then drawn through a catheter (plastic tube placed in a vein) every 30 minutes for 4 hours to measure levels of various hormones and the concentration of acetaminophen. - Euglycemic clamp: This test measures the body's level of insulin resistance by measuring the amount of glucose necessary to compensate for an increased insulin level while maintaining a prespecified blood glucose level.
NCT00064714 ↗	Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes	Completed	AstraZeneca	Phase 2	2003-07-01	This study will determine 1) the safety of AC2993 in patients with type I diabetes; 2) the ability of AC2993 to improve beta cell function; and 3) the effects of immunosuppression on beta cell function. Type I diabetes is an autoimmune disease, in which the immune system attacks the beta cells of the pancreas. These cells produce insulin, which regulates blood sugar. AC2993 may improve the pancreas's ability to produce insulin and help control blood sugar, but it may also activate the original immune response that caused the diabetes. Thus, this study will examine the effects of AC2993 alone as well as in combination with immunosuppressive drugs. Patients between 18 and 60 years of age who have type I diabetes mellitus may be eligible for this 20-month study. They must have had diabetes for at least 5 years and require insulin treatment. Candidates will be screened with a questionnaire, followed by medical history and physical examination, blood and urine tests, a chest x-ray and skin test for tuberculosis, electrocardiogram (EKG), and arginine stimulated C-peptide test (see description below). Participants will undergo the following tests and procedures: Advanced screening phase: Participants undergo a diabetes education program, including instruction on frequent blood glucose monitoring, dietary education on counting carbohydrates, intensive insulin therapy, review of signs and symptoms of low blood sugar (hypoglycemia), and potential treatment with glucagon shots. Patients must administer insulin via an insulin pump or take at least four injections per day including glargine (Lantus) insulin. 4-month run-in phase - Arginine-stimulated C-peptide test: This test measures the body's insulin production. The patient is injected with a liquid containing arginine, a normal constituent of food that increases insulin release from beta cells into the blood stream. After the injection, seven blood samples are collected over 10 minutes. - Mixed meal stimulated C-peptide test with acetaminophen: This test assesses the response of the beta cells to an ordinary meal and the time it takes for food to pass through the stomach. The patient drinks a food supplement and takes acetaminophen (Tylenol). Blood samples are then drawn through a catheter (plastic tube placed in a vein) every 30 minutes for 4 hours to measure levels of various hormones and the concentration of acetaminophen. - Euglycemic clamp: This test measures the body's level of insulin resistance by measuring the amount of glucose necessary to compensate for an increased insulin level while maintaining a prespecified blood glucose level.
NCT00069784 ↗	The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)	Completed	Population Health Research Institute	Phase 3	2003-08-01	The primary objectives of the ORIGIN study were: - To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes; - To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes. The secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce: - total mortality (all causes); - the risk of diabetic microvascular outcomes; - the rate of progression of IGT or IFG to type 2 diabetes.
NCT00069784 ↗	The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)	Completed	Sanofi	Phase 3	2003-08-01	The primary objectives of the ORIGIN study were: - To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes; - To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes. The secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce: - total mortality (all causes); - the risk of diabetic microvascular outcomes; - the rate of progression of IGT or IFG to type 2 diabetes.
NCT00082381 ↗	Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin	Completed	Eli Lilly and Company	Phase 3	2003-06-01	This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).

Clinical Trial Conditions for insulin glargine

Condition Name

Condition Name for insulin glargine
Intervention	Trials
Diabetes Mellitus, Type 2	161
Type 2 Diabetes Mellitus	93
Diabetes	89
Type 2 Diabetes	73

Condition MeSH

Condition MeSH for insulin glargine
Intervention	Trials
Diabetes Mellitus	460
Diabetes Mellitus, Type 2	338
Diabetes Mellitus, Type 1	125
Hyperglycemia	29

Clinical Trial Locations for insulin glargine

Trials by Country

Trials by Country for insulin glargine
Location	Trials
South Africa	98
Romania	96
United Kingdom	94
Brazil	91
Italy	86

Trials by US State

Trials by US State for insulin glargine
Location	Trials
California	131
Texas	130
Florida	117
Georgia	106
Washington	98

Clinical Trial Progress for insulin glargine

Clinical Trial Phase

Clinical Trial Phase for insulin glargine
Clinical Trial Phase	Trials
PHASE4	12
PHASE3	9
PHASE2	2

Clinical Trial Status

Clinical Trial Status for insulin glargine
Clinical Trial Phase	Trials
Completed	433
Terminated	34
Recruiting	31

Clinical Trial Sponsors for insulin glargine

Sponsor Name

Sponsor Name for insulin glargine
Sponsor	Trials
Sanofi	174
Novo Nordisk A/S	102
Eli Lilly and Company	83

Sponsor Type

Sponsor Type for insulin glargine
Sponsor	Trials
Industry	479
Other	305
NIH	10

Insulin Glargine Clinical Trials Update, Market Analysis, and Generic/Biosimilar Launch Projections (2024–2035)

Last updated: July 28, 2026

Executive summary: Insulin glargine remains a large, mature global insulin franchise with rapid share gains from newer glargine biosimilars in multiple markets. Clinical activity is focused on next-generation insulin formats and combination regimens, while payer and label dynamics increasingly determine near-term growth. Patent and exclusivity cliffs vary by jurisdiction and by specific product lineage (original glargine vs follow-on glargines and biosimilars). Market expansion is driven mainly by uptake among basal insulin users, switching from older insulins, and residence time in formularies rather than new mechanism innovation.

---

What is the latest clinical trials update for insulin glargine (2024–2026)?

Answer: Recent insulin glargine trials skew toward (1) comparative efficacy and safety versus reference insulins, (2) switching studies in type 1 and type 2 diabetes, (3) extension data supporting long-term use, and (4) formulation or device-adjacent research tied to basal delivery and adherence. The highest-volume signal historically comes from biosimilar development programs and real-world switching cohorts rather than new-to-class mechanisms.

Where are trials concentrated (type 1 vs type 2 diabetes)?

• Type 2 diabetes (T2D): Most head-to-head and switching evidence targets basal intensification, including addition to oral therapy or intensification from NPH or other basal analogs.
• Type 1 diabetes (T1D): Trials often focus on glycemic control endpoints (HbA1c, fasting plasma glucose) and safety consistency under stable basal dosing, frequently with insulin aspart or lispro as mealtime insulin comparators.

What endpoints dominate insulin glargine trial protocols?

• Glycemic control: HbA1c change from baseline, time-in-range (where used), and fasting glucose.
• Safety: Hypoglycemia rates (overall and severe/nocturnal), injection-site reactions, immunogenicity markers, and weight change.
• Persistence and adherence: Real-world and pragmatic trial designs track treatment continuation and dose adjustment patterns.

What’s the clinical development bias by product category?

• Reference insulin glargine lineage: Lower “new” trial frequency vs biosimilar programs, with more focus on long-term exposure and regional label expansion.
• Biosimilar glargine: Trials center on analytical similarity, pharmacokinetics, efficacy comparability, immunogenicity, and interchangeability/switching.

Market implication: Clinical updates that matter commercially are less about HbA1c deltas and more about real-world interchangeability, payer acceptance, and device usability, which determine formulary retention and volume capture.

---

How big is the insulin glargine market and what is the outlook to 2030?

Answer: Insulin glargine is a core basal insulin category with multi-billion-dollar global sales historically, supported by T2D prevalence and basal insulin intensification. Growth prospects to 2030 depend on (1) biosimilar penetration, (2) price compression and contracting strategies, and (3) the size of the treatable population that remains undertreated for basal insulin.

Revenue drivers

• Therapeutic adoption: Basal insulin initiation and titration among T2D patients inadequately controlled on oral therapy or GLP-1 based regimens.
• Switching: Conversion from NPH or other basal analogs to glargine for lower hypoglycemia risk and improved convenience.
• Payer formularies: Managed entry agreements and biosimilar preferential coverage.

Revenue headwinds

• Price erosion from biosimilars: Competitive contracting compresses unit prices faster than volume offsets.
• Therapy substitution: In some markets, basal insulin share can be diluted by combination injectable strategies and intensification patterns that favor agents with cardiovascular or weight advantages, depending on local clinical pathways.

Scenario-style projection logic (high level)

• Base case: Continued share gains for biosimilar glargine offset by category growth from diabetes prevalence and increased basal insulin penetration.
• Downside: Faster-than-expected switching to other insulin formulations and stronger contracting reduces net revenue per unit.
• Upside: Biosimilar market expansion accelerates due to broader reimbursement coverage and stronger long-term outcomes acceptance.

---

When do insulin glargine products lose exclusivity by region, and how does that affect launches?

Answer: Exclusivity timing differs by product lineage and jurisdiction. For reference insulin glargine and follow-on versions, exclusivity and patent landscapes create staggered biosimilar entry windows. These windows typically influence: (1) earliest permissible regulatory approval, (2) litigation settlement timing, and (3) payer contracting cadence.

What determines “when” entry happens in practice?

• Regulatory approval timing under the applicable pathway (biosimilar versus 505(b)(2) depending on jurisdiction and product classification).
• Patent litigation and automatic stay mechanisms that delay launch even after approval.
• Settlement agreements that define launch dates and sometimes distribution or labeling constraints.

Commercial launch mechanics

• First mover biosimilar: Gains early formulary placement when price offers are aggressive and rebates structured for volume.
• Second/third mover biosimilars: Expand once contracts reset and insurers normalize multiple suppliers.

Market implication: Even if approvals occur around the same time, commercial availability and contract inclusion often create a 6 to 18 month spread in real-world uptake.

---

How many patents protect insulin glargine, and what patent types matter for competition?

Answer: The protective landscape is product-specific and includes a portfolio of formulation, method-of-use, manufacturing, and device-adjacent intellectual property. Practical litigation typically centers on “skinny” formulation or process claims rather than only broad composition-of-matter, which drives whether biosimilar entrants can launch.

Key patent categories that constrain biosimilar glargine

• Composition/formulation patents: Stabilizers, concentration ranges, buffering system composition, and insulin aggregation control strategies.
• Manufacturing method patents: Upstream processing steps, purification, sterile filtration, and formulation mixing controls.
• Method-of-use / clinical regimen patents: Less dominant for glargine than for some specialty therapeutics, but can still affect label scope in specific jurisdictions.
• Device and presentation claims: Cartridge, pen mechanics, and dose delivery systems where protected in relevant markets.

Litigation-relevant patterns

• Biosimilar programs frequently argue non-infringement or invalidity for formulation/process claims while relying on biosimilarity for regulatory bridging.

---

What patents protect insulin glargine in the US Orange Book and how do they differ for biosimilars?

Answer: In the US, the “Orange Book” reflects application listings for approval pathways that are not biosimilars. Insulin glargine products approved as biologics or biosimilars fall under the Biologics Price and Competition (BPCIA) framework and do not map one-to-one to the classic Orange Book “patent listing” structure. This means the most actionable legal landscape is often tied to BPCIA reference product patents and related litigation rather than Orange Book entries.

What to look for commercially

• US patent listings that attach to the reference biologic for BPCIA use.
• Federal district court decisions and settlement dates that set launch conditions.
• Label carve-outs negotiated during settlements.

Market implication: For biosimilar glargine entrants, the enforceability and scope of the reference product’s remaining patents usually govern launch more than the mere existence of additional, later-listed patents.

---

Which biosimilar insulin glargine products are gaining share and why?

Answer: In multiple markets, biosimilar glargines have gained share through aggressive pricing, expanded reimbursement, and physician familiarity with basal analogs. Uptake is highest where insurers implement automatic formulary preference or prefer a small number of basal suppliers.

Share drivers

• Rebate structures: Payer rebates and contracting models that create net price advantages.
• Interchangeability policies: Local rules and payer guidance allowing substitution.
• Clinical confidence: Stability of hypoglycemia outcomes and low immunogenicity signals in extension data.

Why adoption accelerates after early launches

• Initial entry triggers price benchmarks.
• Subsequent entrants expand the number of contracting options.
• Formularies may consolidate after first-year volatility.

---

What patent litigation affects insulin glargine and what are the typical outcomes?

Answer: Insulin glargine litigation commonly resolves via settlements that set a permissible launch date or a launch phase-in schedule. Outcomes tend to protect the reference product by delaying biosimilar commercial rollout until remaining key patents expire or are narrowed.

Typical litigation timeline pattern

1. Patent challenge filing linked to biosimilar development.
2. District court hearings on infringement/validity.
3. Appeals or settlement negotiations after claim construction.
4. Settlement-defined launch with possible labeling or marketing restrictions.

Commercial effect of litigation outcomes

• Even after a court ruling enabling approval, launch can be delayed by appeal or settlement terms.
• Payers may wait for confirmed supply and safety monitoring data.

---

How strong is the insulin glargine patent estate for enforcing exclusivity?

Answer: The strength is generally assessed by whether multiple, independently constraining patents remain active across formulation/process claims that a biosimilar cannot easily “design around.” For mature insulins, estates often narrow to fewer high-leverage patents as earlier, broader claims expire.

What “strong” means in practice

• Multiple patents survive validity attacks.
• Claims are not easily avoided while staying within regulatory biosimilarity constraints.
• Litigation outcomes align with delayed commercial entry rather than prompt workarounds.

---

What generic or biosimilar entry risks exist for insulin glargine?

Answer: For insulin glargine, the key entry risk is not “generic” in the small-molecule sense but biosimilar entry risk governed by BPCIA patent litigation, manufacturing comparability, and immunogenicity consistency expectations. Operational supply and device compatibility also affect launch risk.

Risk map

• Legal: injunction exposure, settlement windows, and appeal timing.
• Scientific/regulatory: immunogenicity and analytical similarity consistency.
• Manufacturing: scale-up risks, batch-to-batch consistency of critical quality attributes.
• Commercial: payer contracting delays and pharmacy benefit management hurdles.

---

How does insulin glargine compare with insulin degludec, glargine-lixisenatide, and other basals?

Answer: Basal insulin selection is driven by dosing flexibility, hypoglycemia profiles, and device/patient preference. Many markets show substitution between basal analogs depending on net pricing, clinical guidelines, and patient-specific hypoglycemia or adherence needs.

Competitive differentiators

• Insulin glargine vs degludec: Duration and hypoglycemia profiles drive clinician choice where evidence and local guidelines favor one basal over another.
• Combination products: Glargine-based combinations may reduce basal titration complexity, impacting glargine monotherapy volume.
• GLP-1 and dual agonist substitution: In some pathways, advanced injectables can delay insulin initiation.

Market implication: The competitive threat is category substitution rather than direct mechanistic replacement, with biosimilar glargine often strongest where payers require low-cost basal options.

---

Formulation and delivery: What formulations are protected for insulin glargine, and how does that constrain biosimilar design?

Answer: Formulation protections typically cover buffer systems, stabilization strategies, concentration-specific characteristics, and aggregation control. Device protections can cover cartridge/pen dosing mechanisms where jurisdictionally enforceable.

What formulation constraints matter

• Critical excipients and buffer components affecting pH and stability.
• Stabilization of insulin hexamer formation and controlled dissociation behavior.
• Storage stability and shelf-life determinants that affect compliance with clinical comparability.

Device and presentation

• Pens and cartridges influence adherence and can be included in IP portfolios in selected markets.
• Device compatibility also affects real-world switching rates.

---

What FDA regulatory status matters for insulin glargine biosimilars and follow-on products?

Answer: In the US, regulatory status is anchored to whether a product is a biologic reference, a biosimilar, or interchangeable (where applicable), and to label scope for basal insulin dosing and patient populations. Post-approval, pharmacovigilance and periodic safety reporting influence payer confidence.

What “regulatory status” changes commercially

• Approval category: biosimilar vs interchangeable designation (where recognized).
• Labeling: whether the biosimilar has equivalent indicated populations and dosing recommendations.
• Post-marketing commitments: influences uptake where robust confidence-building is required.

---

Market projection for insulin glargine to 2035: what drives growth vs price compression?

Answer: Volume growth is supported by diabetes prevalence and basal intensification; revenue growth is tempered by biosimilar-driven price erosion and competitive contracting. By 2030, net revenue tends to track units times net price, where net price declines dominate unless biosimilar switching slows.

Projection framework

• Units: diabetes prevalence, guideline adoption, persistence (staying on basal), and switching from NPH.
• Net price: payer rebates, biosimilar competition intensity, reference product discounting, and procurement dynamics.
• Supply stability: manufacturing expansion and disruption risk in insulin production chains.
• Policy: reimbursement expansions and substitution rules.

By product segment

• Reference insulin glargine: declining share where biosimilars are established.
• Biosimilar glargines: rising share, with growth concentrated in markets with strong reimbursement for biosimilars.
• Combination/regimen products: can siphon basal monotherapy volume but also expand total injectable insulin usage.

---

Key takeaways

• Insulin glargine’s clinical development emphasis is shifting toward biosimilar equivalence, switching evidence, and long-term safety rather than novel mechanism breakthroughs.
• Market expansion to 2030 is primarily a volume story, with revenue constrained by biosimilar-induced price compression and contracting.
• Patent and exclusivity timing remains product- and jurisdiction-specific; litigation outcomes and settlement-defined launch windows drive commercial availability more than regulatory approval alone.
• Competitive pressure is increasingly driven by biosimilar penetration and basal substitution patterns across other long-acting insulins and combination regimens.

---

FAQs

1) What patient populations are most commonly studied in insulin glargine biosimilar switching trials?
T2D intensification populations and stable T1D on basal-bolus regimens, with endpoints focused on HbA1c and hypoglycemia rates.

2) How do payer formulary rules affect insulin glargine biosimilar uptake?
Preferential placement, step-therapy rules, and rebate structures determine whether biosimilars gain rapid volume or are delayed to later lines of therapy.

3) Does insulin glargine device design materially influence market share?
Yes, pen usability and dosing convenience affect persistence and switching readiness, which directly drives volume capture during competitive transitions.

4) What are the main manufacturing-related risks for insulin glargine biosimilars at launch?
Batch consistency of critical quality attributes, scale-up performance, and ensuring stable insulin aggregation control across manufacturing sites.

5) How do insulin glargine combination products affect monotherapy projections?
They can reduce glargine monotherapy share by changing intensification pathways, even as total injectable basal-regimen patients increase.

---

References

(No sources were provided in the prompt, and no verifiable, citable dataset could be included without generating unverifiable claims.)